医药行业研究：阿斯利康DURVALUMAB获FDA批准用于治疗LS-SCLC

太平洋证券股份...12-09

报告摘要市场表现：2024 年12 月6 日，医药板块涨跌幅+1.88%，跑赢沪深300 指数0.57pct，涨跌幅居申万31 个子行业第21 名。各医药子行业中，医疗研发外包(+6.32%)、疫苗(+2.11%)、医院（+2.02%）表现居前，血液制品（+1.10%)、其他生物制品(+1.20%)、体外诊断（+1.35%)表现居后。个股方面，日涨幅榜前3 位分别为广生堂(+19.99%)、...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2490923527?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-09 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2490923527","market":"us","top_or_hot":-1,"title":"医药行业研究：阿斯利康DURVALUMAB获FDA批准 用于治疗LS-SCLC","media":"太平洋证券股份...","content":"<div>\n<p>报告摘要市场表现：2024 年12 月6 日，医药板块涨跌幅+1.88%，跑赢沪深300 指数0.57pct，涨跌幅居申万31 个子行业第21 名。各医药子行业中，医疗研发外包(+6.32%)、疫苗(+2.11%)、医院（+2.02%）表现居前，血液制品（+1.10%)、其他生物制品(+1.20%)、体外诊断（+1.35%)表现居后。个股方面，日涨幅榜前3 位分别为广生堂(+19.99%)、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209120209ab68bd3c&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药行业研究：阿斯利康DURVALUMAB获FDA批准 用于治疗LS-SCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药行业研究：阿斯利康DURVALUMAB获FDA批准 用于治疗LS-SCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209120209ab68bd3c&s=b><strong>太平洋证券股份...</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>报告摘要市场表现：2024 年12 月6 日，医药板块涨跌幅+1.88%，跑赢沪深300 指数0.57pct，涨跌幅居申万31 个子行业第21 名。各医药子行业中，医疗研发外包(+6.32%)、疫苗(+2.11%)、医院（+2.02%）表现居前，血液制品（+1.10%)、其他生物制品(+1.20%)、体外诊断（+1.35%)表现居后。个股方面，日涨幅榜前3 位分别为广生堂(+19.99%)、...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209120209ab68bd3c&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2456880835.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209120209ab68bd3c&s=b","article_id":"2490923527","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241209120209ab68bd3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2490923527","pubTimestamp":1733673600,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"行业要闻：12 月6 日，阿斯利康宣布其重磅PD-L1 抑制剂Imfinzi已获得美国FDA 的批准，用于治疗接受铂类同步放化疗后病情未进展的局限期小细胞肺癌成人患者。Durvalumab 是一种人源化的单克隆抗体， 通过与PD-L1 的结合，durvalumab 阻断PD-L1 与PD-1 和CD80 蛋白的结合，进而抑制肿瘤的免疫逃逸机制。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4585":"ETF&股票定投概念","BK4568":"美国抗疫概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4588":"碎股","AZN":"阿斯利康","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Pharmaceutical industry research: AstraZeneca DURVALUMAB approved by the FDA for the treatment of LS-SCLC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1},"content_text":"报告摘要市场表现：2024 年12 月6 日，医药板块涨跌幅+1.88%，跑赢沪深300 指数0.57pct，涨跌幅居申万31 个子行业第21 名。各医药子行业中，医疗研发外包(+6.32%)、疫苗(+2.11%)、医院（+2.02%）表现居前，血液制品（+1.10%)、其他生物制品(+1.20%)、体外诊断（+1.35%)表现居后。个股方面，日涨幅榜前3 位分别为广生堂(+19.99%)、博腾股份(+13.48%)、热景生物(+12.45%)；跌幅榜前3 位为四环生物（-10.00%）、葫芦娃(-9.98%)、爱朋医疗（-8.60%)。行业要闻：12 月6 日，阿斯利康（AstraZeneca）宣布其重磅PD-L1 抑制剂Imfinzi（Durvalumab）已获得美国FDA 的批准，用于治疗接受铂类同步放化疗（cCRT）后病情未进展的局限期小细胞肺癌（LS-SCLC）成人患者。Durvalumab 是一种人源化的单克隆抗体， 通过与PD-L1 的结合，durvalumab 阻断PD-L1 与PD-1 和CD80 蛋白的结合，进而抑制肿瘤的免疫逃逸机制。（来源：阿斯利康，太平洋证券研究院）公司要闻：通化东宝（600867）：公司发布公告，子公司东宝紫星（杭州）生物医药有限公司完成了注射用THDBH120 的一项关键Ia 期临床试验并获得临床试验总结报告，研究结果显示达到主要终点目标。马应龙（600993）：公司发布公告，近日收到国家药品监督管理局核准签发的关于MYL 软膏（暂定虎麝止血止痛膏）的《药物临床试验批准通知书》，将于近期开展适应症为痔疮的临床试验。圣湘生物（688289）：公司发布公告，近日收到由国家药品监督管理局颁发的《医疗器械注册证》，公司产品人偏肺病毒核酸检测试剂盒（荧光PCR 法）获得批准。风险提示：新药研发及上市不及预期；政策推进超预期；市场竞争加剧风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490923527"}

医药行业研究：阿斯利康DURVALUMAB获FDA批准 用于治疗LS-SCLC

精彩评论

医药行业研究：阿斯利康DURVALUMAB获FDA批准用于治疗LS-SCLC